top of page
Browse by category
Search
REVEAL-1: Sustained post-GLP-1 weight maintenance after a single Revita procedure
Fractyl Health has announced positive 6-month results from its open-label REVEAL-1 Cohort. The REVEAL-1 Cohort is an open-label study in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. The REVEAL-1 data show that patients who underwent a single Revita procedure after discontinuing GLP-1 therapy maintained both stable body weight and glycaemic control through 6 mont
Fractyl’s REMAIN-1 study shows Revita maintained weight loss after GLP-1 discontinuation
Fractyl Health has revealed results from the REMAIN-1 Midpoint Cohort, supporting the potential for Revita to be the first therapy to...
Early data shows Revita has potential to prevent weight regain after GLP-1 discontinuation
Fractyl Health has announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results...
German Real-World Registry shows meaningful and sustained weight loss for at least one year after a single Revita endoscopic procedure
Fractyl Health has announced new weight maintenance and blood sugar clinical results from the Company’s German Real-World Registry for...
FDA grants Breakthrough Device Designation for Fractyl’s Revita in weight maintenance for people with obesity who discontinue GLP-1s
The FDA has granted Breakthrough Device Designation (BDD) for Fractyl Health’s Revita System for use in the maintenance of weight loss...
Revita German Real-World Registry: First 14 participants continue to demonstrate sustained improvements in blood glucose and weight
Six-month follow-up data from Fractyl Health’s Revita German Real-World Registry has reported that he first 14 consented registry...
FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
Revita results in weight loss and sustained weight maintenance without weight regain at one year
The latest weight maintenance data from a pooled analysis of patients enrolled in Revita (Fractyl Health) clinical studies across the EU...
Fractyl’s Revita DMR System commercially available in Germany
Fractyl Health has announced the commercial availability of its Revita DMR System in Germany, an endoscopic procedural therapy that is...
Fractyl Health reports latest Revita DMR outcomes for T2DM
New data from Fractyl Health’s Revita-1 and Revita-2 studies presented at Digestive Disease Week 2022 builds on this earlier evidence to...
Browse by tag
bottom of page